ANELIXIS THERAPEUTICS
Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts with a portfolio focused on immune modulatory drugs for neurodegenerative diseases with a focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD). Anelixis Therapeutics is committed to advancing treatments that will have a meaningful impact on the lives of patients by helping them battle back their disease progression.
ANELIXIS THERAPEUTICS
Industry:
Biotechnology Clinical Trials Medical Product Research
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.anelixistherapeutics.com
Total Employee:
1+
Status:
Closed
Contact:
+1.617.599.6514
Total Funding:
6.86 M USD
Technology used in webpage:
Google Google Cloud Ninja Forms
Similar Organizations
AMES Technology
AMES Technology primarily develops subacute clinical trials.
BIOSA Technologies
BIOSA Technologies is an enzymatic biotechnology company headquartered in Toronto, Canada.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
Impact Proteomics
Impact Proteomics makes all inclusive kits for protein, peptide, and proteome sample preparation and clean up.
ITeos Therapeutics
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
LyGenesis
LyGenesis is an organ regeneration company that facilitates organ regeneration and transplant.
STC Biologics
STC Biologics is a biotechnology company that offers biologics drug research and development services.
Venquis Therapeutics
Venquis Therapeutics is a biotechnology company that focuses on chemically targeted protein degradation.
Current Employees Featured
Founder
Official Site Inspections
http://www.anelixistherapeutics.com
- Host name: 143.185.239.35.bc.googleusercontent.com
- IP address: 35.239.185.143
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Anelixis Therapeutics"
Anelixis Therapeutics Company Profile 2024: Valuation, Investors ...
Anelixis Therapeutics was acquired on 14-Sep-2020. Who acquired Anelixis Therapeutics? Anelixis Therapeutics was acquired by Eledon Pharmaceuticals. Data Transparency. Meet our …See details»
Anelixis Therapeutics, LLC Company Profile | Cambridge, MA ...
Find company research, competitor information, contact details & financial data for Anelixis Therapeutics, LLC of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Novus Therapeutics Announces Acquisition of Anelixis …
Sep 14, 2020 Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, autoimmune diseases, and neurodegenerative ...See details»
Anelixis Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Anelixis Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 news, Drug:Tegoprubart.See details»
Anelixis Therapeutics CEO and Key Executive Team | Craft.co
Anelixis Therapeutics's Founder, CEO & Director is Steven Perrin. Other executives include Pamela Gustafson, Vice President of Clinical Operations & Compliance; Michelle A. Baron, …See details»
Anelixis Therapeutics - Contacts, Employees, Board Members, …
Anelixis Therapeutics is a biotechnology company that facilitates pre-clinical drug development.See details»
Announces Acquisition of Anelixis Therapeutics
Sep 15, 2020 IRVINE - Novus Therapeutics, Inc. ('Novus') (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. ('Anelixis'), a privately held …See details»
Anelixis Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Apr 25, 2018: Venture Round - …See details»
ALS TDI and Neurimmune Partner to Advance Treatments for ALS
Dec 6, 2013 ALS TDI is the world’s largest independent ALS/MND drug development-focused nonprofit organization. It currently has partnerships with dozens of pharmaceutical and …See details»
Anelixis Therapeutics to Provide Pipeline of Clinical Candidates for …
Feb 10, 2014 Anelixis Therapeutics, LLC is a mission-aligned translational medicine and drug development company created by the ALS Therapy Development Institute in 2013.It uses …See details»
ALS Therapy Development Institute and Neurimmune Partner to …
Jun 12, 2013 ALS TDI is the world’s largest independent ALS/MND drug development-focused nonprofit organization. It currently has partnerships with dozens of pharmaceutical and …See details»
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Sep 16, 2020 IRVINE, CA & BOSTON, MA, USA I September 14, 2020 I Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis …See details»
Acquisition of Anelixis Therapeutics Fuels Hopes for ALS
Sep 14, 2020 About Anelixis Therapeutics Anelixis Therapeutics, Inc. was a clinical stage, privately held biotechnology company developing treatments for patients with …See details»
Team - Eledon Pharmaceuticals, Inc.
At MyoKardia she built and led a world class development organization culminating in the company’s $13.1 billion acquisition by Bristol Myers Squibb in November 2020. ... (formerly …See details»
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Sep 15, 2020 Novus Therapeutics, Inc. announced it has completed the acquisition of Anelixis Therapeutics, Inc. a privately held clinical stage biotechnology company developing a next …See details»
Anelixis Therapeutics Announces a Financing Led by BVF Partners …
Nov 18, 2019 Anelixis Therapeutics’ Forward Looking Statements This press release contains forward-looking statements, all of which are qualified in their entirety by this cautionary …See details»
Novus Acquires Anelixis, Plans to Move AT-1501 Into Phase 2 Trial...
Sep 21, 2020 AT-1501 is an antibody against a protein called CD40 ligand (CD40L), found on the surface of some immune cells and involved in regulating the immune response, which can …See details»
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Sep 14, 2020 Senior management team with extensive drug development and commercialization experience, including Dr. David-Alexandre“ DA” C. Gros as CEO and Dr. …See details»
Home - Anelixis Pharmaceuticals
About us. “…at Anelixis, we are passionate about patients and their health, and we never give up in the face of any challenge, which we prefer to explore andSee details»